One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

Older antiretroviral regimens raise diabetes risk in HIV-positive - picture 1

Older antiretroviral regimens raise diabetes risk in HIV-positive

7 December 2017, 11:56 contact@life4me.plus

HIV-positive adults who initiated older formulations of antiretroviral therapy are more likely to develop type 2 diabetes than patients who initiated therapy between 2010 and 2015, according to study findings reported in BMJ Open Diabetes Research & Care, Healio reports.

“Combination antiretroviral therapy (ART) has dramatically increased the life expectancy of people living with HIV; however, they are now developing comorbidities associated with prolonged survival and aging, and these may be occurring at earlier ages than in the general population,” Faizal Samad, clinical trials coordinator with the AIDS Research Program at St. Paul’s Hospital in Vancouver, British Columbia, Canada, and colleagues wrote in the study background. “Many [people living with HIV], particularly those who received older antiretroviral treatments, experienced peripheral fat atrophy, visceral fat accumulation and metabolic comorbidities, including dyslipidemia and impaired glucose homeostasis, which can lead to increased risk for cardiovascular disease and other related morbidities.”

Samad and colleagues analyzed data from 1,065 patients with HIV aged at least 50 years who initiated ART before July 2015 and did not have diabetes at baseline. All participants were treated at a large urban HIV outpatient clinic at St. Paul’s Hospital through July 2015. Researchers identified diabetes incidence through database records and chart review. The rate of new-onset diabetes was defined as the number of cases of diabetes divided by the total number of person-years of follow-up. A final, multivariable analysis used data from 703 participants — excluding patients who started ART before 1997 and did not have plasma HIV viral load results in the period before initiating therapy.

During a median of 13 years, researchers observed 235 new diabetes diagnoses among the entire cohort, for an incidence rate of 1.61 cases per 100 person-years.

Of the 703 patients included in multivariable analyses (89% men; 73% white), 132 developed diabetes. Among those with diabetes, 43% had hepatitis C virus coinfection, 8% had hepatitis B virus coinfection and 38% had a history of injection drug use. The median HbA1c was 5.8% for the 36% of patients with diabetes who had HbA1c results available, according to researchers.

Patients who initiated ART between 1997 and 2004 were more likely to develop diabetes vs. those who initiated ART between 2010 and 2015 (30% vs. 2%; P < .001). Increased length of time on ART also increased the odds of developing type 2 diabetes.

“Longer exposure to ART agents and the use of older drugs were associated with a higher incidence of [diabetes] in our study,” the researchers wrote. “On the other hand, obesity, HCV coinfection, and older age were not associated with the incidence of [diabetes] in this cohort. The incidence of [diabetes] is likely to decline in [people living with HIV] who initiated ART more recently with the use of newer ART agents.” – by Regina Schaffer.


Latest News

All news - picture 2

Chemsex is associated with an increased risk of HIV transmission and sexual infections

The use of gay, bisexual and other men who have sex with men (#MSM), crystallized methamphetamine, mephedrone, γ-hydroxybutyrate or γ-butyrolactone, and to a lesser extent cocaine and ketamine during sexual intercourse, or the so-called " the phenomenon is relatively new, ...

23 May 15:48

All news - picture 3

ART drug Juluca appears in European pharmacies

Pharmaceutical company ViiV Healthcare, specializing in the development and production of medicines for HIV treatment, reported that the European Commission issued a permit for the implementation in Europe of the combined drug Juluca (#dolutegravir 50 mg / rilpivirine 25 ...

22 May 14:30

All news - picture 4

Truvada in the US will be used to reduce the risk of HIV transmission among adolescents

Gilead Sciences, Inc. announced that the FDA approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents.

17 May 15:01

All news - picture 5

A patient has died from AIDS in Switzerland because he was not paid for HIV treatment

As it became known to the media, an HIV-positive patient died from AIDS in Switzerland in the end of 2017. He was being refused of a medical treatment due to missing necessary health insurance, and the insurance company refused several times to pay for the treatment because ...

1 May 14:29